Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1

Several studies suggest that nitric oxide (NO) production is impaired in diabetes mellitus. Reduced levels of NO could contribute to cardiovascular mortality. Furthermore, NO synthesis is impaired in glutathione (GSH)-depleted human umbilical vein endothelial cells and GSH is reduced in patients wit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2001, Vol.24 (1), p.37-41
Main Authors: MARTINA, V, BRUNO, G. A, ZUMPANO, E, ORIGLIA, C, QUARANTA, L, PESCARMONA, G. P
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Blood Platelets - enzymology
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Endothelium, Vascular - metabolism
Erythrocytes - metabolism
Female
General and cellular metabolism. Vitamins
Glutathione - administration & dosage
Glutathione - blood
Glutathione - therapeutic use
Humans
Male
Medical sciences
Middle Aged
Nitric Oxide - biosynthesis
Nitric Oxide Synthase - blood
Nitric Oxide Synthase Type III
Pharmacology. Drug treatments
Plasminogen Activator Inhibitor 1 - blood
Umbilical Veins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several studies suggest that nitric oxide (NO) production is impaired in diabetes mellitus. Reduced levels of NO could contribute to cardiovascular mortality. Furthermore, NO synthesis is impaired in glutathione (GSH)-depleted human umbilical vein endothelial cells and GSH is reduced in patients with type 2 diabetes mellitus (T2DM). We tested the hypothesis that treatment with GSH may improve platelet constitutive NO sinthase (cNOS) activity in patients with T2DM. Fifteen patients with T2DM underwent a treatment with GSH 600 mg/day i.m. for 10 days. With respect to the basal values on the 10th day of treatment, the red blood cell GSH concentration and platelets cNOS increased (1.4+/-0.1 vs 1.9+/-0.1 micromol/10(10) RBC, p
ISSN:0391-4097
1720-8386
DOI:10.1007/BF03343806